Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ia/Ib trial of ACH 2928 in volunteers and treatment-naive patients with genotype 1 hepatitis C

Next Previous
Trial Profile

Phase Ia/Ib trial of ACH 2928 in volunteers and treatment-naive patients with genotype 1 hepatitis C

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 May 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACH 2928 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

Most Recent Events

  • 21 Apr 2012 Results assessing monotherapy in patients with genotype 1a or 1b hepatitis C have been presented at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL-2012) according to an Achillion media release.
  • 05 Dec 2011 Preliminary results published in an Achillion Pharmaceuticals media release.
  • 11 Jul 2011 Planned number of patients changed to 68, according to information in an Achillion Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top